<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203329</url>
  </required_header>
  <id_info>
    <org_study_id>PTL 0601</org_study_id>
    <nct_id>NCT04203329</nct_id>
  </id_info>
  <brief_title>AMBULATE Same Day Discharge Registry</brief_title>
  <official_title>A Multi-center, Prospective, Single Arm Registry to Evaluate Procedural Outcomes Using the Cardiva VASCADE MVP VVCS Closure Device After Catheter-based Atrial Fibrillation Interventions for Patients Who Are Discharged the Same Day.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiva Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiva Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, prospective, single-arm post market registry, designed to collect both
      performance and complication outcomes when same day discharge is enabled by the study device,
      in sealing multiple femoral venous access sites at the completion of ablation procedures for
      atrial fibrillation with or without another arrhythmia, performed through 6 - 12 Fr inner
      diameter (maximum 15F OD) introducer sheaths.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Days</target_duration>
  <primary_outcome>
    <measure>VASCADE MVP VVCS Procedure Success</measure>
    <time_frame>1 day</time_frame>
    <description>Patients do not require next day hospital intervention* due to access site-related complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Complication Rate</measure>
    <time_frame>15 Days +/- 5 Days</time_frame>
    <description>On a per-limb basis, the rate of combined major venous access site closure-related complications attributed directly to the closure method within 15 ± 5 days of discharge (i.e., &quot;device-related&quot; with no other likely attributable cause).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Same Day Procedure Success</measure>
    <time_frame>1 day</time_frame>
    <description>Patients do not require next day hospital intervention for any procedure-related reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained VASCADE MVP VVCS Procedure Success</measure>
    <time_frame>15 Days +/- 5 Days</time_frame>
    <description>Patients do not require hospital intervention within 15 days of discharge due to access site-related complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>intra-procedural</time_frame>
    <description>The ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with the VASCADE MVP VVCS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Complication Rate</measure>
    <time_frame>15 Days +/- 5 Days</time_frame>
    <description>On a per-limb basis, the rate of combined minor venous access site closure-related complications attributed directly to the closure method (i.e., &quot;device-related&quot; with no other likely attributable cause.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Vascular Closure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Femoral Venous Vascular Closure</intervention_name>
    <description>Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing ablation procedures for atrial fibrillation with or without another
        arrhythmia, performed through 6 - 12 Fr inner diameter (maximum 15F OD) introducer sheaths.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pre-Operative Inclusion:

        All subjects are required to meet the following inclusion criteria in order to be
        considered eligible for participation in this trial:

          1. ≥18 years of age;

          2. Capable and willing to give informed consent;

          3. Acceptable candidate for an elective, non-emergent catheter-based atrial fibrillation
             ablation procedure via the common femoral vein(s) using a 6 to 12 Fr inner diameter
             (max 15F OD) introducer sheath

          4. Is accompanied by a person who will be available to assist the subject for 24 hours
             post-procedure and/or has access to emergency services;

          5. Is willing/able to stay overnight at the hospital per physician discretion.*

          6. Able and willing to complete a 15 (± 5) days post-procedure follow-up contact

          7. Acceptable candidate for emergent vascular surgery, and/or manual compression of the
             venous access site;

        Intra-Operative Inclusion:

        Subjects will be excluded from participating in this study if any of the following
        exclusion criteria occur during the index procedure:

        General Intra-op Exclusion Criteria:

          1. Any attempt at femoral arterial access during the procedure;

          2. Any procedural complications that may extend routine recovery, ambulation and
             discharge times;

          3. If the physician deems that a different method should be used to achieve hemostasis of
             the venous access sites, or that the subject should not attempt ambulation according
             to the protocol requirements;

          4. All venous access sites must comply with the following exclusion criteria, assessed
             immediately prior to enrollment:

               1. Difficult insertion of procedural sheath or needle stick problems at the onset of
                  the procedure (e.g., multiple stick attempts, accidental arterial stick with
                  hematoma, &quot;back wall stick&quot;, etc.) in any of the study veins;

               2. A procedural sheath &lt; 6 Fr or &gt; 12 Fr in inner diameter is present at time of
                  closure;

               3. A procedural sheath &gt; 12 Fr inner diameter at closure. *

               4. Venous access site location is noted to be &quot;high&quot;, above the inguinal ligament
                  (cephalad to lower half of the femoral head or the inferior epigastric vein
                  origin from the external iliac vein);

               5. Intra-procedural bleeding around sheath, or suspected intraluminal thrombus,
                  hematoma, pseudoaneurysm, or AV fistula;

               6. Length of the tissue tract, the distance between the anterior venous wall and
                  skin, is estimated to be less than 2.5 cm.

        Exclusion Criteria:

        Pre-Operative Exclusion:

          -  Subjects will be excluded from participating in this study if they meet any of the
             following criteria prior to initiation of the index procedure:

               1. Advanced refusal of blood transfusion, if it should become necessary;

               2. Active systemic infection, or cutaneous infection or inflammation in the vicinity
                  of the groin;

               3. Pre-existing immunodeficiency disorder and/or chronic use of high dose systemic
                  steroids;

               4. Known history of bleeding diathesis, coagulopathy, hypercoagulability, or current
                  platelet count &lt; 100,000 cells/mm3;

               5. Severe co-existing morbidities, with a life expectancy of less than 12 months;

               6. Currently involved in any clinical trial that may interfere with the outcomes of
                  this study in the opinion of investigator;

               7. Femoral arteriotomy in either limb with any of the following conditions:

                    1. access within &lt; 10 days

                    2. any residual hematoma, significant bruising, or known associated vascular
                       complications

                    3. use of a vascular closure device within the previous 30 days;

               8. Femoral venotomy in either limb with any of the following conditions:

                    1. access within &lt; 10 days

                    2. any residual hematoma, significant bruising, or known associated vascular
                       complications

                    3. use of a vascular closure device

               9. Any planned procedure involving femoral arterial or venous access in either limb
                  within the next 30 days;

              10. Any history of deep vein thrombosis, pulmonary embolism or thrombophlebitis;

              11. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less
                  than 30%;

              12. Females who are pregnant, planning to become pregnant within 3 months of the
                  procedure, or who are lactating;

              13. Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than
                  20 kg/m2);

              14. Unable to routinely walk at least 20 feet without assistance;

              15. Known allergy/adverse reaction to bovine derivatives;

              16. Administration of low molecular weight heparin (LMWH) within 8 hours before or
                  after the procedure;*

              17. Planned procedures or concomitant condition(s) that may extend ambulation
                  attempts beyond routine ambulation and/or hospital discharge time (e.g., staged
                  procedure, serious co-morbidity, uncontrolled obstructive sleep apnea, congestive
                  heart failure), * in the opinion of the Investigator.

        Intra-Operative Exclusion:

        Same Day Discharge (all criteria apply):

          -  In the Investigator's opinion, the subject is a candidate for Same Day Discharge per
             protocol (e.g. no new pericardial effusion, post-procedure diuresis not needed, etc.).

          -  If procedural heparin is used, it was/will be reversed at or before venous closure. *

          -  Physician or designee will be on site for discharge evaluation.

          -  Case completed in time for subject to be reasonably recovered and discharged according
             to protocol.

          -  All femoral venous access sites are planned to be closed with the MVP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Terry Alverson</last_name>
    <phone>408-470-7119</phone>
    <email>terry_alverson@cardivamedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justin Ballotta</last_name>
    <phone>408-470-7105</phone>
    <email>jballotta@cardivamedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedStar Washington</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meseret Deressa, MD</last_name>
      <phone>202-877-0141</phone>
      <email>meseret.y.deressa@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Zayd Eldadah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

